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Summary In addition to bacteria and inflammatory cells, the sputum of patients with
bronchiectasis contains mediators that damage the airway epithelium and promote
inflammatory change. The deleterious effects of these mediators, such as neutrophil
elastase, reduce host defences and consequently perpetuate the propensity to
recurrent infection. This ‘vicious cycle’ of infection and inflammation in bronch-
iectasis suggests that long-term antibiotic therapy might be beneficial in these
patients by reducing microbial load and, in doing so, inhibit inflammation in the lung
allowing tissue repair to occur. Short courses of antibiotics achieve clinical
improvements and also have been shown to reduce the levels of harmful mediators
in the sputum. This article will cite the studies reported for long-term antibiotic
treatment in bronchiectasis and overall there seems to be benefits for patients with
chronic sputum purulence. The evidence that supports the postulated pathological
mechanisms will also be discussed. Important issues in clinical practice such as the
usefulness of antibiotic sensitivities, the evolution of resistance patterns, and drug
delivery will also be discussed.
r 2003 Elsevier Science Ltd. All rights reserved.
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Introduction
Bronchiectasis is a chronic lung disease associated
with permanent dilatation of the bronchi and
usually excess mucopurulent secretions.1 Many
individuals with this disorder endure significant
impairment in their quality of life due to persisting
cough with sputum production, dyspnoea, constitu-
tional upset, and infective episodes. Whilst it is
possible to have a normal life expectancy with
bronchiectasis,2 at times exacerbations of the
condition can be sufficiently severe as to be life
threatening and a number of patients experience
accelerated loss of lung function and progress to
respiratory failure and premature death.3
The effectiveness of antibiotics in the treatment
of acute infective exacerbations of this condition is
established4–6 although patients often require high-
er than standard doses.7 Short courses of anti-
biotics result in both a reduction in sputum volume
as well as clearing of purulence.5 Patients report
improvements in general health and, in parallel,
there are favourable changes in markers of infec-
tion such as temperature, white cell count, and
serum inflammatory indices. In contrast, the
benefits of long-term antibiotic treatment in
bronchiectasis are a lot less clear cut. One would
anticipate that this treatment strategy would
benefit patients in various ways including suppres-
sion of symptoms, a reduction in exacerbation rates
and improved quality of life. Furthermore, if
antibiotics influenced the pathological processes
that led to disease progression, then long-term
treatment might conceivably alter the natural
history of the condition. This might be particularly
important for the group of individuals with severe
disease and deteriorating pulmonary function.
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Conversely, there is a widely held view that
antibiotics used in this way may promote resistance
patterns amongst colonising organisms. This review
will discuss the theoretical rationale for the use of
long-term antibiotics in bronchiectasis and the
clinical evidence that exists.
A potential mechanism for long-term
antibiotic treatment
The pathogenesis of the airway dilatation and
destruction is complex. Although there are numer-
ous predisposing conditions, an underlying cause
may be impossible to identify and idiopathic
bronchiectasis constitutes approximately half of
the cases seen.8 Regardless of the aetiology,
characteristic pathophysiological changes are seen
in the lung and these include excess mucus
production and impaired mucociliary transport.9
The epithelial lining shows loss of columnar ciliated
cells, an inflammatory cell infiltrate and occasional
ulceration.10 The loss of normal mucosal integrity
and a fully functioning mucociliary escalator may
be the initiating event which allows microbial
colonisation of the airway and in turn generates
an inflammatory responses. Further damage to the
airway epithelium weakens host defences and
perpetuates a continuum of infection, inflamma-
tion and progressive damage to the lung. End-stage
bronchiectatic lung shows gross destruction to the
airways as well as chronic fibrotic change. Any
therapeutic intervention in bronchiectasis should
be designed to break or weaken the link between
infection and inflammation. A reduction in both the
number of acute infections and the microbial load
in the lung should result in a diminution in
inflammatory cell influx and tissue damage and
eventually allow healing. These processes are
collectively described by the Vicious Cycle hypoth-
esis11 and this is the basis of the case put forward
by protagonists for long-term antibiotics.
The chronic expectoration of purulent or muco-
purulent sputum by individuals with bronchiectasis
is central to the understanding of effective
management strategies, including long-term anti-
biotics. Sputum often reveals evidence of both
infection and inflammation. Positive microbiologi-
cal cultures for bacteria such as Haemophilus
influenza and Pseudomonas aeruginosa are direct
evidence of ongoing colonisation/infection in the
lung and may inform decisions regarding the
antibiotic treatment of acute exacerbations. Per-
haps more relevant to the issue of long-term
antibiotics is the presence in the sputum of markers
of inflammation. Serum proteins, including albu-
min, are found in the sputum of these patients and
the sputum/serum albumin ratio is a correlate of
airway inflammation in bronchiectasis. In addition
proteinases, such as neutrophil elastase, super-
oxide radicals, and inflammatory cells are found in
the sputum and are also surrogate indices of
inflammation and ongoing damage. Purulent secre-
tions contain high levels of these factors1 and the
positive correlation between neutrophil elastase
and albumin concentrations indicates the associa-
tion of pus with bronchial wall inflammation.12
Neutrophil elastase is a serine proteinase and
stimulates mucous gland hyperplasia,13 as well as
damaging ciliated epithelial cells.14,15 It is also
postulated that high levels of neutrophil elastase
may directly promote microbial colonisation. This
effect is mediated via detrimental actions on the
function of IgA (allowing bacterial adherence) 16
and also on IgG (failure to fix complement).17
Proof of the role of these pro-inflammatory
mediators in bronchiectasis would be strengthened
if measurable clinical improvements were to coin-
cide with a transformation of sputum from chronic
purulence to mucoid following treatment. Stockley
et al. showed such a change in a group of 15
patients treated with antibiotics, taken during a
stable phase for 14 days.18 Twelve of 15 patients
treated with amoxycillin, co-trimoxazole, or tetra-
cycline showed macroscopic clearance of their
sputum from purulent to mucoid and associated
reductions in the elastase activity. In parallel with
these changes, there were significant reductions in
the sputum/serum albumin ratio indicative of
improvements in the levels of bronchial inflamma-
tion. Four patients ceased to expectorate any
sputum during the course of antibiotic treatment.
All patients showed a return of sputum purulence
and elastase activity within 1 week of stopping
treatment.
A further study by the same group showed
benefits in favour of prolonged antibiotic treatment
(over 4 months) in a group of bronchiectatic
patients with chronic purulent elastase positive
expectoration.19 Ten patients received amoxycillin
(250mg t.i.d., 3 g b.i.d., or nebulised 500mg in
5ml sterile water b.i.d.). Despite seven patients’
sputum cultures suggesting amoxycillin-resistant
organisms, all 10 individuals demonstrated a
transition to mucoid (or mucopurulent) sputum
during the course of treatment. In parallel with
this, there were improvements in patients symptom
scores (well being and cough), sputum volume and
systemic inflammatory markers (acute-phase serum
proteins). As with the previous study, there were
significant falls in sputum neutrophil elastase and
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sputum/serum albumin ratios. Following the termi-
nation of antibiotic treatment, the elastase and
sputum/serum albumin ratio rose again to near pre-
treatment levels. In addition, the authors also
demonstrated a chronic systemic inflammatory
state in ‘stable’ bronchiectasis compared with
healthy controls, as measured by serum a1-antic-
hymotrypsin levels. This was most marked in
patients with chronic purulent sputum.
A previous clinical trial evaluating the benefits of
antibiotic treatment in bronchiectasis showed
similar results to the aforementioned studies,
indeed the data helped inform the hypothesis
relating to sputum markers and ongoing inflamma-
tion.20 In this non-randomised study, Hill et al.
showed that patients with mucoid sputum re-
sponded well to short courses of conventional dose
amoxycillin for exacerbations, but that patients
with mucopurulent or purulent sputum required
higher doses over a longer period. About 60% of the
patients with purulent sputum responded to amox-
ycillin 3 g b.i.d. (compared to 17% when treated
with 250mg t.i.d.). A further group of patients
failing to respond to high-dose oral treatment
showed improvements on nebulised amoxycillin
over 4 months. Despite appearing to be clinically
stable prior to treatment, the patients in the
mucopurulent and purulent groups reported im-
provements in well being and symptoms. After
treatment, mucopurulence and purulence returned
rapidly in these patients. The authors discuss the
importance of dose and the relevance of tissue/
sputum penetration in cases with chronic puru-
lence. They emphasise the need to exceed the
mean inhibitory concentration for organisms colo-
nising the lung and found little correlation between
in vitro sensitivity testing and clinical response.
A further study by Ip et al. reported changes in
sputum neutrophil chemotactic activity (NCA) and
elastase-like activity (EA) amongst a group of 12
bronchiectatic patients with acute exacerbation
treated for 2 weeks with antibiotics.21 All were
chronic purulent sputum producers and were
followed up at 2 and 6 weeks after treatment.
They showed a significant increase in NCA and EA
during exacerbation which returned to normal
within 1 week of antibiotic treatment. In parallel
with this there were clinical responses. The second
week of antibiotics did not result in a further fall in
NCA or EA. At 2 and 6 weeks, the inflammatory
markers remained at the same level as they had
been at baseline prior to the exacerbation. The
authors concluded that acute antibiotic treatment
was of benefit but were unable to show that this
treatment resulted in any improvement in chronic
airway inflammation. All the 12 patients were
noted to expectorate mucopurulent or purulent
secretions.
Clinical trial evidence
Compared with other respiratory disorders, there
are relatively few trials looking at the use of long-
term treatment with antibiotics in bronchiectasis.
A recent summary of systematic reviews carried out
by the Cochrane Collaboration examining rando-
mised controlled trials in the treatment of airway
diseases found 68 reviews derived from 641 trials.22
When broken down by disease there were only six
reviews dealing with bronchiectasis compared with
33 for asthma. The patient base for the asthma
reviews numbered 26,680 subjects, the figure for
the bronchiectasis reviews was 181. Clearly, asthma
is a more common disorder; however, these
statistics demonstrate the shortfall in controlled
data for bronchiectasis and limits the evidence
base from which guidelines for disease manage-
ment can be drawn. Acknowledging the paucity of
data, do the existing studies examining the use of
long-term antibiotic treatment allow us to draw
any conclusions about possible benefits and risks?
The trial results on which we must make these
decisions are described.
The first study, albeit not a randomised con-
trolled trial, looking at the use of long-term
antibiotics was published in 1952.23 Harris et al.
studied 62 patients, 38 of whom suffered from
bronchiectasis. Patients received chloramphenicol
1 g b.i.d. or t.i.d. for between 2 and 6 months.
Thirty-six of the 38 bronchiectasis patients experi-
enced sustained reductions in their sputum volume
by 50% or more. Following this period, the
antibiotic was stopped and 14 patients went on to
take placebo, the remainder discontinued all
treatment. Relapse of symptoms occurred within
3 months of stopping the antibiotic regardless of
whether the subjects had gone onto placebo.
The following year, the use of chlortetracycline
250mg b.i.d. was reported by McVay et al.24
Twenty-nine patients (not all of whom were
bronchiectatic) were allocated, non-randomly, to
receive antibiotic (20 patients, for a mean of 11
months) or placebo (9 patients, for a mean of 7.7
months). Sixteen patients treated with chlortetra-
cycline showed reductions in frequency and sever-
ity of infection compared to only two patients in
the placebo group.
The MRC trial (1957), remains one of the most
informative studies reporting the effects of long-
term antibiotic treatment.25 One hundred and
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twenty-two patients were randomised to receive
penicillin (38 patients), oxytetracycline (44 pa-
tients), or placebo (40 patients) over 1 year. Three
patients died, one in each group, four patients
defaulted (two oxytetracycline, two placebo), one
patient was excluded following the diagnosis of
cystic fibrosis (CF), and two patients failed to
tolerate the study medication. The final analysis
was therefore based on 112 patients. Interestingly,
none of the data were subjected to statistical
analysis. Within 2 weeks, the 24 h sputum volume in
the oxytetracylcine group was reduced to 55% of
pre-treatment volume and the purulent fraction
was reduced by 50%. These changes were sustained
throughout the trial. For the penicillin and placebo
groups, the 24 h sputum volume was reduced to 70%
and 80%, respectively. During the year on treat-
ment there were definite advantages for patients
treated with oxytetracycline with respect to days
off work and confinement to bed. All groups showed
improvements for cough, haemoptysis and dys-
pnoea.
Cherniak et al. reported a trial evaluating
tetracycline, oleandomycin/penicillin combined,
penicillin alone and placebo over 3–22 months.26
Not all the patients had bronchiectasis (45 of 67
subjects). The groups differed in terms of disease
severity with discrepancy between 24 h sputum
volumes and chronic expectoration of either
mucoid or purulent sputum. The tetracyline group
suffered significantly less acute lower respiratory
tract infections and fewer days with fever than the
placebo group. Otherwise, there were no signifi-
cant differences between groups. The heterogene-
ity of the patients enrolled makes interpretation of
this trial difficult.
The trial reported by Currie et al. in 1990 studied
38 patients over 32 weeks27 and was designed to
test the vicious cycle hypothesis using high-dose
long-term treatment. Nineteen subjects were
randomised to receive Amoxyl sachets 3 g b.i.d. or
matched placebo. There were nine drop-outs (four
amoxycillin, five placebo) two of these within the
first 2 weeks and therefore their data were not
analysed. The withdrawals were due to failure to
respond (five subjects), adverse events (three
subjects) and non-compliance (one subject). Data
from 36 patients were analysed and the primary
end point of the study was objective response
assessed by changes in 24 h sputum volume, sputum
culture results, or FEV1. A significantly higher
proportion of the amoxycillin-treated patients
responded compared to the placebo group (11/17
and 4/19, respectively). The number of exacerba-
tions between the groups was not different
although there was a reduction in the severity of
exacerbations in the amoxycillin-treated patients.
The 24 h sputum volume was reduced to 20% of pre-
treatment levels for the amoxycillin group com-
pared to 80% of pre-treatment volume for the
placebo group. Whilst there was a reduction in H.
influenzae cultured from the sputum in the actively
treated patients, those individuals who continued
to culture this bacteria showed a tendency towards
increasing resistance. There were 21 patients who
cultured P. aeruginosa (13 amoxycillin, eight
placebo). There were no differences between the
groups for adverse events.
The experience of 10 patients who had taken
ciprofloxacin for a mean period of 4127273 days
(range 90–860) was reported by Rayner et al.28 The
dose varied between 500 and 1500mg taken in
divided doses, two or three times a day. Nine
patients had positive sputum cultures at the
beginning of treatment (five P. aeruginosa, all
sensitive to ciprofloxacin, three H. influenzae,
and one Streptococcus pneumoniae). Following
treatment, six patients showed no growth, two of
whom had been colonised with P. aeruginosa. One
patient grew S. pneumoniae instead of P. aerugi-
nosa and two continued to yield P. aeruginosa which
had become resistant to ciprofloxacin. The devel-
opment of resistance to ciprofloxacin by P. aerugi-
nosa was associated with clinical deterioration.
Seven patients reported improvements in their
condition on treatment and there were significant
reductions in exacerbations and hospital admis-
sions. There were also significant improvements in
peak flow and residual volume on lung function
testing. There were no adverse events and the
therapy was considered to be safe. The authors
comment that ciprofloxacin, whilst concentrated in
bronchial mucosa is only bacteriostatic against S.
pneumoniae and therefore not likely to effect
eradication of this organism in patients showing
this bacteria on sputum culture.
A further trial evaluating the use of quinolones in
the prophylaxis of exacerbations of chronic re-
spiratory tract infections was published by Wata-
nabe et al.29 Fifty-eight patients, inclusive of only
19 bronchiectatics were studied for 6 months. The
remaining patients’ diagnoses included emphyse-
ma, chronic bronchitis, previous tuberculosis, and
diffuse panbronchiolitis. All of the individuals for
this trial were selected on the basis that their
chronic illness was characterised by recurrent
infection. Exacerbations in the 6 months prior to
study entry was a prerequisite for inclusion. The
patients were randomised to receive either oflox-
acin 200mg o.d. (regimen one) or ofloxacin 200mg
t.i.d. taken for 2 weeks at a time every fortnight
(regimen two). The corrected mean exacerbation
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rate per 6 months was reduced from pre-study 2.47
to intra-study 0.59 for regimen one and from pre-
study 2.66 to intra-study 0.95 for regimen two. The
drugs were well tolerated and only one P. aerugi-
nosa isolate (out of 12 patients showing this
organism) developed resistance to ofloxacin but
without clinical deterioration. The authors con-
cluded that both regimes were effective at redu-
cing exacerbations, but found no statistical
difference between them. They favoured the use
of ofloxacin 200mg daily.
The same group published a further study
comparing ciprofloxacin, erythromycin, or a com-
bination of the 2 over 6 months.30 Not all the
patients had a diagnosis of bronchiectasis (19 out of
50) although six patients were diagnosed with
diffuse panbronchiolitis. As previously, all the
patients suffered from recurrent lower respiratory
tract infection. The results showed significant
protection against exacerbations in the patients
randomised to receive ciprofloxacin or the combi-
nation of ciprofloxacin and erthryomycin. There
were no significant adverse events and only one P.
aeruginosa isolate developed resistance to cipro-
floxacin.
The data reported by Koh et al. were derived
from a group of 25 children randomised to receive
roxithromycin (4mg/kg) or placebo over 3
months.31 All of the children had proven bronch-
iectasis and heightened airways responsiveness to
methacholine (PC20o2.5mg/ml). The study was
based on the unproven premise that bronchial
hyperreactivity was a feature of bronchiectasis32
and that this played a part in the pathogenesis of
the condition by inhibiting respiratory clearance
mechanisms. Following treatment, the patients
randomised to roxithromycin had a significant
reduction in sputum purulence, leucocyte scores
and airways responsiveness to methacholine. No
changes were seen in the placebo group. The paper
does not state whether the subjects had chronic
expectoration of purulent sputum and seven of the
children had co-existing asthma.
Tsang et al. studied 37 chronic stable bronchiec-
tatic patients to evaluate the benefits of low-dose
erthromycin treatment for 2 months.33 Ten of the
erythromycin patients and six of the placebo
patients showed positive sputum cultures for P.
aeruginosa. The primary outcomes, sputum volume
and lung function (FEV1), were significantly im-
proved on erythromycin compared with placebo.
No changes were seen for sputum pathogens,
leucocytes or leukotrienes. Neutrophil elastase
was not measured.
There are a number of trials showing the benefits
of inhaled antibiotics in the management of CF
patients.34 Orriels et al. randomised 17 patients
with non-CF bronchiectasis, all of whom were
colonised with P. aeruginosa, to receive inhaled
ceftazidime 1 g b.i.d. and tobramycin 100mg b.i.d.
or standard management alone.35 The trial dura-
tion was 1 year and all patients received a 2-week
course of intravenous antibiotics prior to embarking
on the study period. There were significant benefits
in favour of the inhaled strategy for both numbers
of admissions and in-patient days. There were no
differences for lung function between the two
groups, which showed a progressive decline, nor
any differences for resistance patterns for P.
aeruginosa.
A second clinical trial looking at the use of
inhaled antibiotics in bronchiectasis was reported
by Barker et al.36 Seventy-four patients with
bronchiectasis and chronic infection with P. aeru-
ginosa were randomised to receive tobramycin
300mg b.i.d. or matched placebo over 4 weeks.
The primary end point was a reduction in P.
aeruginosa density on sputum culture (expressed
as log10 colony forming units/g sputum). The study
showed significant reductions of microbial density
on sputum culture and the organism was eradicated
in 35% of actively treated patients 2 weeks after
discontinuing the treatment phase (i.e. at 6
weeks). No eradication of P. aeruginosa was seen
in the placebo group. The authors reported
objective improvement in 62% of the tobramycin
patients and 38% of the placebo patients. In
contrast, the subjective assessments indicated a
non-significant trend for increase in cough, wheeze
and dyspnoea for the tobramycin group. There
were no differences for resistance patterns be-
tween treatments not for FEV1.
A recent systematic review has drawn together
this evidence and included the randomised con-
trolled trials. Where possible the data have been
synthesised to undertake meta-analysis.37 Only six
trials fulfilled the criteria for inclusion25,27,33,35,36
and therefore a number of the aforementioned
studies, despite contributing to the evidence base,
can only be discussed in isolation and have not been
a part of summary statistics for treatment effects.
The review included a total of 302 patients, 40% of
which were derived from one study.25 The anti-
biotic duration varied from 4 weeks to 1 year. There
were 40 withdrawals due to adverse events or
intolerable side effects. Due to the diversity of the
trials, it was only possible to do limited meta-
analysis. Response rates during the course of
treatment showed significant effects in favour of
active intervention, Peto odds ratio 0.3, 95%
confidence interval, 0.14, 0.63, although for
exacerbation rates there were no differences in
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favour of antibiotics. Outcome measures looking at
withdrawals and lung function showed no differ-
ences between interventions and placebo.
Summary
To arrive at a consensus on the issue of long-term
antibiotic treatment in the management of bronch-
iectasis is not easy given the diversity of the
condition in terms of aetiology, severity, and in
particular, microbial culture results. This article
has made no attempt to consider the issue of
aetiology in the context of long-term antibiotic
treatment as insufficient data are available.
Furthermore, the evidence that does exist repre-
sents extreme variety in terms of study design, end
points (sputum markers, symptoms, lung function),
duration (ranging from a few weeks to 1 year),
subject selection (children/adults), antibiotic se-
lection (arbritrary/specific), microbiology (exclu-
sively Pseudomonas colonisation or otherwise), and
drug delivery (oral/parenteral/nebulised).
The issue of P. aeruginosa colonisation is worthy
of special attention. Pseudomonas colonisation is
associated with a worse prognosis in bronchiectasis
as demonstrated by physiological and radiographic
studies.38,39 Whilst most of the trials evaluating
patients with mixed sputum culture results (i.e. not
P. aeruginosa), have shown that in vitro testing
does not predict clinical outcomes, individuals
colonised with P. aeruginosa do require tailored
antibiotic regimes. Only two trials specifically
addressed the issue of P. aeruginosa and these
studies adopted inhaled regimes.34,35 The authors
of the oral quinolone studies did not confine
themselves to patients colonised by P. aeruginosa
(nor exclusively bronchiectatic patients in two
trials) and further research looking at oral regimes
against this bacteria remains to be reported. On
the basis of the evidence reported, nebulised
antibiotics appear to be effective anti-pseudomo-
nal treatment in both CF and non-CF bronchiecta-
sis.
The use of macrolide antibiotics in a number of
studies is of interest. It is possible that these drugs
may exert benefits through non-antibacterial me-
chanisms. Diffuse pan-bronchiolitis has been recog-
nised as a progressive condition characterised by
sputum production, rhinosinusitis, and chronic P.
aeruginosa colonisation.40 Erythromycin has been
shown to be effective treatment for this condition
despite the Pseudomonas colonisation41 and this is
supported by pre-clinical data suggesting non-
antibacterial properties of macrolides possibly
targeted against inflammatory effects of P. aerugi-
nosa.42 Therefore, the studies reporting macrolides
should be interpreted with this issue in mind.
The systematic review of six randomised con-
trolled trials warrants brief discussion. Notwith-
standing the limited meta-analyses and the issues
of diversity already discussed, the results support a
marginal advantage in the use of long-term anti-
biotic treatment. However, it is noteworthy that
three of the included studies did not state a
primary end point nor give details of power
calculations which raises the doubt about type II
statistical errors for negative analyses. This is
particularly relevant to measures of lung function
which were negative in all the review trials with
the exception of the study reported by Tsang.33
Given the data showing the effects of antibiotic
treatment on neutrophil elastase and sputum/
serum albumin concentrations, it is disappointing
that the review trials did not specifiy the patients
who had chronic expectoration of purulent sputum.
Furthermore, many of the other clinical trials also
failed to make this observation and therefore
correlation of clinical responses and possible
mechanisms for these patients is lacking.
Overall, the trials cautiously support the benefits
of long-term antibiotic treatment although these
advantages are only maintained during treatment
and no enduring benefits have been reported.
There is a body of evidence that suggests that this
intervention does reduce ongoing airways inflam-
mation and therefore might be expected to
influence the natural history of the disease. It
would appear that any advantage will be relevant
to those patients who expectorate purulent spu-
tum. For individuals colonised with Pseudomonas,
specific antibiotic regimes should be selected and
there may be a role for long-term nebulised
treatment. For patients not colonised with P.
aeruginosa, in vitro sensitivity testing does not
predict clinical responses. Furthermore, the emer-
gence of antibiotic resistance does not appear to be
a major issue for these patients. As a rule the
treatments are well tolerated. Further, carefully
designed and focused research is required to take
this clinical challenge forward. In a disease of
diminishing prevalence, the difficulties of designing
adequately powered trials and recruiting sufficient
numbers of patients are daunting. Furthermore, in
a condition of such differing aetiologies, it should
be anticipated that there might be an even greater
heterogeneity in clinical responses to treatment.
There is still considerable debate as to the optimal
outcome measures and we have yet to learn
how best to identify with certainty those patients
who are likely to progress to severe disability
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and who are most likely to benefit from targeted
interventions.
Practice points
* There is some evidence that long-term
antibiotics have a role in the management
of patients with chronic sputum purulence
* The treatment is well tolerated and emer-
ging resistance does not occur in most
patients
* In patients not already colonised with P.
aeruginosa, in vitro sensitivities may not
predict clinical outcomes
* P. aeruginosa requires specific antibiotic
regimes
* Nebulised treatment has a role in manage-
ment
* Macrolides may work through non-antibac-
terial mechanisms
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